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Abstract
Epigenetics is an emerging research topic that is being tested as a potential cure for cancer. Epigenetics is a non-genetic
influence that shapes the phenotype. Epigenetics effects gene expression, but does not cause any changes in the DNA.
DNA methylation patterns is one such epigenetic change in the cell that has huge potential for cancer treatment.
Scientists have observed that many cancerous genes express signs of either hypermethylation or hypomethylation. The
key for the treatment is that epigenetic changes are reversible, which opens the door to potential drugs to cure cancer
and other diseases.
Introduction

Materials and Methods

Epigenetics literally means “above” the gene and is a new
study of research in biology that explains how environmental
factors impact one’s biology. Epigenetic mechanism explains
how there are over 220 different cell types in an adult organism even though they all have the same DNA. All cells in each
organism contains the same DNA, but their cell function differs in different cells, based on “qualitative and quantitative
differences in gene expression.” (Gibney, Nolan, 2010). Bone
cells, skin cells, heart cells, all have the same DNA, but their
functions are completely different. This cell differentiation is
a specific pattern of gene expression where certain parts
of the DNA are turned on or off in each type of cell. This
specific pattern of gene expression is passed down from
cell to cell. Epigenetics is defined as “the study of mitotically
(and potentially meiotically) heritable alterations in gene expression that are not caused by changes in DNA sequence
(Gibney, Nolan, 2010). One researcher compares genes and
epigenetics to a computer, where genes are the hardware and
epigenetics is the software telling the hardware how to function. There is a certain balance of epigenetics that is normal
and healthy for the cell, but when these balances are changed
and the epigenetic mechanisms become unregulated there
may be alterations in gene expression, and can ultimately
lead to cell transformation and malignant outgrowths. There
are three major types of epigenetic changes; DNA methylation, Covalent Posttranslational Histone Modification, and
Small Inhibitory RNA-mediated signaling Pathways. Mainly,
Epigenetic processes, including DNA methylation and histone
modification, influence gene expression at the transcription
level.

In order to understand how epigenetics can be a potential cure
for cancer, many journals and articles were retrieved from Touro
College’s library database. Those articles and the references
they listed formed the basis for exploring this topic.

DNA methylation is the most studied epigenetic factor and
that is what will be discussed in this paper. DNA methylation occurs through the covalent addition of a methyl group
(CH3) to the 5 position of a cytosine generating 5-methylcytosine (Stein, Davis, 2012). Methyl groups protrude into
the major groove of DNA and change the biophysical characteristics of the DNA. Cells can methylate and demethylate
DNA, which effects specific gene expression. These epigenetic changes can experience multigenerational inheritance; not
only does it change the phenotype of the first individual, but
the methylation can pass onto further generations.

Correlation between DNA methylation and gene
silencing
An experiment with mice and coat color phenotype and body
weight measurement exposed the correlation between methyl
groups and silencing of gene expression. A group of pregnant
mice that were genetically identical were assembled, half the
group were fed a diet rich in methyl groups (here soy), and the
control half their regular diet. All these mice had the agouti
gene, which when expressed gives the mouse a yellow color
and causes obesity.The offspring of the mice that had the methyl
rich diet were thin and brown, whereas the offspring of the
mice that did not eat the methyl groups remained yellow and
fat. They both have the agouti gene, but the brown mice had a
methyl group attached to the agouti gene which shut it down.
Bisulfite sequencing methylation analysis of CpG sites in the
promoter region of the agouti gene (Avy IAP) showed a statistical increased average percentage of cells methylated of the mice
given the methyl rich diet. This was a simple experiment to see
how DNA methylation affects gene expression because it was
easy to see when the gene was on and off based on the phenotype color switch and body measurement. Also, this epigenetic
tag was passed down to the offspring’s of these mice, and continued until they ate a diet without enough methyl groups. Soy
has an active ingredient that methylates DNA.This research may
explain why there is a lower incidence of cancer among Asians
compared to Westerners, because Asians eat diets rich in soy
and may explain why Asians who emigrate to America are more
likely to develop cancer than their family back home. (Dolinoy,
et. al. 2006)

DNA methylation causes gene silencing
Although a correlation was noted between gene activation and
methylation, the authors wanted to prove conclusively that
DNA methylation is the cause of the gene silencing. They were
not positive yet which was the cause and which was the effect,
they though that it might be possible for the gene inactivation
to cause the DNA methylation. An experiment was carried
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out that proved that DNA methylation caused gene inactivation. The experiment was conducted on the E2a region of Ad2
DNA. The region was cloned, and then half of the gene was
methylated in vitro with HpaII DNA methyltransferase and then
microinjected into the nuclei of X. laevis oocytes.The key is that
the scientists ensured that the methylated DNA only remained
methylated for 24 hours after microinjection.There was no synthesis of Ad2 specific RNA in the methylated DNA cells until 24
hours after injection. The control did however readily express
the Ad2 specific RNA.The experiment results demonstrate that
methylation plays an actual role in causing genome inactivation
because at the end of the 24 hour period, there is no genome
expression, yet that does not cause the methylation to continue, which proves that methylation is not a consequence of a
lack of gene expression. The gene expression inactivation only
occurred in the narrow window that the Gene was methylated
(Doerfler, 1981).

How it causes gene silencing
Cytosine methylation inhibits the transcription of genes. When
there is an extra methyl group on the DNA, it becomes inaccessible for protein binding for gene expression. The methyl group
interferes with the binding of the protein to its specific DNA
to transcribe it.

Cancer
Typically, it was believed that cancer was caused by genetic defects such as, mutations, amplifications, deletions and translocations, which affected the cancer cell and provided it with the
advantage to survive and metastasize. However, today, it is clear
that there is another system of equal importance that is liable in
causing cancer, and that is epigenetic marks.Today cancer is considered a genetic and epigenetic disease. This epigenetic alterations which can cause cancer have been termed epimutations.
This is extremely important because damage to a cell’s DNA
is permanent, whereas epigenetic change is reversible. (Stein,
Davis, 2012).

Proof that epigenetic changes can cause cancer
Take arsenic which is known to cause cancer of the skin, liver, lung,
and bladder, but actually does not cause DNA mutations, as demonstrated in standard mutagenic assays. However in 2010, researchers
found that arsenic caused cancer by epigenetic mechanisms. This
was a groundbreaking epigenetic mechanism that cause cancer,
and that is a major breakthrough in terms of finding a cure. One
group of researchers studied CpG islands of over 14000 genes
in people who were exposed to high levels of arsenic, verified by
their urinary arsenic levels. It was found that these genes were
epigenetically modified from the arsenic exposure, and researchers
found that a tumor suppressor gene was silenced. This is called
a “tumor suppresorome,” which is a group of 17 confirmed or
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recognized tumor suppressor genes that are silenced in human
cancers, most of these through abnormal methylation patterns.
(Stein, Davis, 2012)

Two ways that DNA Methylation can have an
impact on carcinogenesis
One is by hypomethylation and one is by hypermethylation.
Hypomethylation is a decrease in the normal amount of methylation on DNA. Hypomethylation usually occurs at repetitive
chromosomal sequences where DNA is normally methylated.
Researchers found that four out of five cancer patients had
significant hypomethylation in their cancer cells as compared
to their neighboring cancer free cells. Hypomethylation, in
decreasing the normal amount of methylation of the gene,
decreases the normal amount of gene silencing, i.e. increases
gene expression. This can result in an activation of genes with
growth and tumor promoting functions (Lund, Lohuizen, 2004).
Additionally, hypermethylation, or the increase in the amount
of DNA methylation can cause a negative impact on the cells,
and can lead to carcinogenesis. This hypermethylation is found
at CpG islands, which are most likely found in the 5’ regulatory
region of the gene, which are not methylated. Here the extra
methylation causes gene silencing, and tumor suppressor genes
are being silenced (Feinberg, 2001). In one experiment, it was
revealed that the mRNA for RL7NX3, a tumor suppressor gene
involved in several cancers, is suppressed in primary cutaneous
melanoma and in metastatic tumors. CpG Island, which are usually not methylated and transcriptionally active, have been found
to be abnormally hypermethylated during the development of
cancer, particularly in tumor suppressor genes. Genes involved
in cell cycle regulation, DNA repair, (to name two) are very
epigenetically susceptible (Stein, Davis, 2012).

Hypermethylation of GSTP1 and prostate cancer
Methylation of GSTP1 is the most common epigenetic alteration
described in several tumors, such as prostate cancer, endometrial
cancers, and breast cancers. GSTP1 catalyzes the s conjugation
of GSH, which protects the cell from cytoxic and carcinogenic
agents. Methylation of GTSP1 gene occurred in 90% of prostate
cancer tissue from surgical specimens. In this experiment, the
tissue samples from 144 patients who were having a prostate
biopsy were examined. Forty two out of the 144 patients were
diagnosed with prostate cancer. Additionally, there was hypermethylation of the GTSP1 gene in 31 out of those 42 patients,
and only in 2 out of the 102 patients who did not have cancer.
Since epigenetics is a cause of carcinogenesis, and, therefore, cells
will exhibit hypermethylation at the onset of the cancer, there is
potential for using hypermethylation as a biomarker to detect
the cancer.These genes, and other genes that exhibit hypermethylation in the early onset of cancer, may eventually be useful as
a biomarker to detect prostate cancer. However, methylation of
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Epigenetics and age correlation

Table 1 shows a list of that when hypermethylated become
cancerous.This means that it may be possible to use
hypermethylation as a biomarker to detect cancer early on.
the GTSP1 gene may indicate another cancer, and does not indicate prostate cancer, specifically. However there is potential for
mapping out hypermethylation of other genes and using a multi
gene profile to improve specificity for cancers. Azacytidine has
been found to reverse the hypermethylation of the GTSP1 gene,
and reactivate transcription (Miano et. al. 2007).

Epigenetic tests on identical twins
The best way to study epigenetics is on monozygotic twins
because they have the same genetic material, but still have difference in cell expression and their phenotype. There is a high
discordance rate between identical twins for many diseases,
even those thought to be genetic. Epigenetic changes through
environmental variances can be the answer to the phenotypic
differences of identical twins. Researchers in Madrid studied 80
identical twins in a range of 3 to 74 years old. Thirty five percent of the twin pairs had significantly different methylcytosine
genomic content. Researchers observed that the difference in the
methylcytosine pattern for the twins increased with the age of
the twins. The youngest twin pair had their epigenetic pattern
the most similar, whereas the oldest pair’s epigenetic pattern was
very different. Also, they found that twins who had not grown up
together had the greatest difference of 5’ methyl cytosine levels.
These differences in methylation of their cells is what causes the
gene expression and phenotype of monozygotic twins to differ.
This study indicates that methylation patterns are one reason
why twins with the same DNA may have different phenotypes.
Additionally, the fact that the epigenetic differences were more
distinct in twins who spent less of their lives together indicates
that major role the environment plays into translating a general
genotype into different phenotypes detectable. External factors
play a great role in gene expression by changing the pattern of
epigenetic modifications (Fraga, et. al. 2005).

For every cell division there is a potential for epigenetic damage.
As a person ages, their cells are forced to divide again and again
to replenish any tissue damage that may have occurred. Each time
this happens there is a chance for epigenetic damage through an
altering of the normal methylation pattern of the cell. Scientists
can take tissues from an older person and can estimate by looking
at the epigenetic patterns of the DNA in a particular tissue how
old the person is, because these epigenetic changes accumulate as
a person ages. For a cell, aging is counted by how many times the
cell has divided. The more damage a cell has, the more times it is
forced to divide and replenish, and the more chances that there
is going to be an abnormal pattern of methylation in this cell. For
example, smoking and sun exposure can cause skin tissue injury.
When a person’s skin peels from a sunburn its cells repair that
damage by dividing and replenishing those cells. In these cases,
the sun and cigarette exposure can cause actual DNA damage,
but they also just damage the tissue which leads to cellular repair
of that injury through cell division, and leads to a gradual accumulation of epigenetic damage. Lungs of heavy smokers can look
20 times older than nonsmokers. This can explain why there is a
higher incidence of cancer among older individuals. With age, the
amount of exposure he or she has had to environmental toxins
increases, which can ultimately lead to an abnormal methylation
pattern (Nova, 2007).

Epigenetic therapy
Epigenetic therapy works to repair the normal methylation pattern of the cell.This is done through DNA methylation inhibition.
5’Azacytidine and 5-aza-2’-deozycytidine (Decitabine/DAC), the
two most advanced drugs for epigenetic therapies for cancer.
Both are in clinical use (Silverman, et. al. 2006). They are DNA
methyltransferase inhibitors and work by trapping DNA methyl transferases thereby inhibiting methylation, and restoring the
gene’s normal expression. DNA methyl transferases, known as
DMTAs, are the enzymes that are responsible for DNA methylation. DAC incorporates into DNA and forces the methyl
transferases to form irreversible covalent bonds to DNA. These
methyl transferases are then targeted for deletion in the proteasome. Then, cells divide, without DMTA and there is now DNA
hypomethylation and reactivation of genes that were silenced
from the extra methyl groups. However, DAC can also cause cytotoxicity when given in high doses, and therefore dosage must
be monitored. A positive side to epigenetic therapy of cancer is
the minimal side effects which is due to the fact that scientist can
give low doses of the medication with successful results.Whereas
for cancer drugs scientist have to give the highest dose possible
of the medication to kill all the harmful cells, epigenetic therapy,
does not necessitate high doses of the drug because it is not
aiming to kill all the cells, but rather just to change the abnormal
methylation patterns of the cancer cells. DAC was not tested
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on young children or on pregnant women. The drug does not
target normal methyl tags for two reasons. Firstly, drugs target
the area of the most cellular divisions, and in this case, they are
going to target the cancer cells and leave the normal cells alone.
Additionally, modification of epigenetic patterns has a large effect on cancer cells but will hardly have any long term effect on
the behavior of normal cells. When the drug was stopped the
normal cells returned to their normal epigenetic pattern, while
the cancer cells, now healthy cells with normal methylation patterns, did not revert to tumorigenesis. There is potential for all
other cancers that have an epigenetic origin. Myelodysplastic syndrome, also known as MDS, and Acute Myelogenous Leukemia,
also known as ALS are easier targets for these drugs because the
cancer cells are in the blood and have easy access to drugs. (Issa,
2013) These drugs do not work with solid tumors yet. A reason
that is likely is because it is much harder to incorporate the drugs
into these cells, which are multiplying much more slowly than
hematological cancers. Right now, these drugs are being tested
with solid state tumors and the results have been promising. In
the laboratory the scientists have been able to adjust the abnormal epigenetic pattern of the solid state tumor with these drugs,
and are working to mimic these results in the body. The catch is
that these drugs that prevent methylation can reactivate expression of multiple silenced genes, even genes that we want silenced,
like oncogenes, which are genes that have the potential to cause
cancer. Therefore, the demethylation can be harmful as well as
helpful. For example, oncogene NT5E is transcriptionally silenced
by methylation in breast cancer. Therefore hypomethylating that
area would activate that oncogene and not be helpful.This is why
in the future it is important to have some sort of epigonomic
profiling- to identify potentially deleterious silenced genes before
using epigenetic therapy to pharmacologically reverse resistance
(Hatzmichael, Crook, 2013).

MDS, AML and other lymphomas
Myelodysplastic syndrome, or MDS, and Acute Myelogenous
Leukemia, are cancers of the bone marrow. MDSs are hematological disorders that usually progresses into AML. Years ago,
patients diagnosed with MDS were basically given a death sentence, there was no cure, and no hope for any remission. It was
soon realized that MDS was epigenetic in origin. Researchers
thought to study the epigenetic pattern in patients with MDS
because of the fact that the patients with the disease have an
average age of 70. Diseases that target older individuals likely
have an epigenetic component in it. MDS patients have aberrant
methylation of their CpG loci and silencing of multiple genes.
MDS was therefore an ideal candidate for epigenetic therapy,
and indeed results were positive. Decitabine was given to over
100 patients for Acute Myelogenous Leukemia. In fifty percent
of the patients the disease disappeared fully. Twenty five percent
achieved some improvements. However, another 25% did not
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respond to the drug, or the drug worked for a short amount of
time but then stopped working (Nova, 2007).

Conclusion
All in all, the discovery that many cancers have an epigenetic
origin, has opened a new path for potential cures for cancer.This
was possible because epigenetic abnormalities are reversible. It
is integral to realize that everything one does affects his or her
health, and the health of future generations. One’s diet and what
one is exposed to can affect his epigenome and subsequently his
future generation’s phenotype. We are not just the product of
our biology, we are also its cause.
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